- The prospective, open-label ADDITIONS (Controlled-Trials.com #ISRCTN53233058) study evaluated the effectiveness of ivabradine for symptom relief and improvement in quality of life (QoL) in 2,330 patients with stable angina in clinical practice.
- Resting heart rate, angina symptoms (Canadian Cardiovascular Society class), nitrate use, QoL, and concomitant medication were documented.
- The study duration was four months with patients being on optimized medical standard therapy for angina at baseline; all patients received beta blockers.
- In the current subgroup analysis, we report the effects of ivabradine in two cohorts of patients with and without previous percutaneous coronary intervention (PCI) treatment.
- After four months ivabradine effectively reduced angina symptoms and improved QoL with good general tolerability, independent of previous PCI status.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Servier Deutschland GmbH, Munich, Germany. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. 